Peter Voorhees

A specialist from the Levine Cancer Institute in Charlotte, US

Best podcasts with Peter Voorhees

Ranked by the Snipd community

Jan 14, 2022 • 13min

Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.